Prospectus amendment ...filed with the SEC yesterday Good to see!!!
As at the date of this Prospectus, the Company anticipates using the net proceeds to the Company from any offering of Securities primarily to fund its acquisition strategy. The Company’s acquisition approach generally targets companies that are either: (i) heavily respiratory weighted companies with gross revenue in the range of US$5 to $20 million, and consistent annual EBITDA (earnings before interest, taxes, depreciation, and amortization) margins between 10% and 20% or more; (ii) sub US$5 million revenue targets with the strategic goal of expanding the Company’s payer mix and expanding our geographical footprint across new states to be become a national DME provider; or (iii) targeting substantially larger opportunities that would be more meaningful in terms of revenue, EBITDA, active patient base and geographical operating footprint. The Company believes that the maximum size that the Company can raise under this Prospectus of $200,000,000 (or the equivalent in other currencies based on the applicable exchange rate at the time of the offering) will provide sufficient room to draw upon in order to complete strategic acquisitions in the future if, as and when any such opportunities arise, and is expected to position the Company to aggressively pursue its corporate strategy to grow the business. The Company has spent the last several years building and solidifying its platform and within the last year has pivoted into a strategy more focused on growth, both internal and by acquisition and other strategic transactions. For any specific acquisition for which the Company raises funds for under the Prospectus, the Company intends to include details of the acquisition in any Prospectus Supplement and any other additional disclosure as required by applicable securities laws. "